Evidence map›Paper›PMID 38149239›Full record

ArticleFrontiers in immunology2023

Unraveling the enigma of B cells in diffuse large B-cell lymphoma: unveiling cancer stem cell-like B cell subpopulation at single-cell resolution.

Fengling Liu, Jie Zheng, Gaohui Yang, Lin Pan, Yanni Xie, Siyu Chen, Jinwei Tuo, Jinxia Su, Xiuyi Ou, Rongrong Liu

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Breaking Immunosuppression to Enhance Cancer Stem Cell-Targeted Immunotherapy.International journal of biological sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Fengling Liu *Department of Hematology, The first Affiliated Hospital of Guangxi Medical University, Nanning, China.
Jie Zheng *Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China.
Gaohui YangDepartment of Hematology, The first Affiliated Hospital of Guangxi Medical University, Nanning, China.
Lin PanDepartment of Hematology, The first Affiliated Hospital of Guangxi Medical University, Nanning, China.
Yanni XieDepartment of Hematology, The first Affiliated Hospital of Guangxi Medical University, Nanning, China.
Siyu ChenDepartment of Hematology, The first Affiliated Hospital of Guangxi Medical University, Nanning, China.
Jinwei TuoDepartment of Hematology, The first Affiliated Hospital of Guangxi Medical University, Nanning, China.
Jinxia SuDepartment of Hematology, The first Affiliated Hospital of Guangxi Medical University, Nanning, China.
Xiuyi OuDepartment of Hematology, The first Affiliated Hospital of Guangxi Medical University, Nanning, China.
Rongrong LiuDepartment of Hematology, The first Affiliated Hospital of Guangxi Medical University, Nanning, China.
Guangxi Medical University · CNFirst Affiliated Hospital of GuangXi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Diffuse large B-cell lymphoma (DLBCL) represents the most prevalent form of aggressive non-Hodgkin lymphoma. Despite receiving standard treatment, a subset of patients undergoes refractory or recurrent cases, wherein the involvement of cancer stem cells (CSCs) could be significant. Methods: We comprehensively characterized B cell subpopulations using single-cell RNA sequencing data from three DLBCL samples and one normal lymph tissue. The CopyKat R package was employed to assess the malignancy of B cell subpopulations based on chromosomal copy number variations. CIBERSORTx software was utilized to estimate the proportions of B cell subpopulations in 230 DLBCL tissues. Furthermore, we employed the pySCENIC to identify key transcription factors that regulate the functionality of B cell subpopulations. By employing CellphoneDB, we elucidated the interplay among tumor microenvironment components within the B cell subpopulations. Finally, we validated our findings through immunofluorescence experiments. Results: Our analysis revealed a specific cancer stem cell-like B cell subpopulation exhibiting self-renewal and multilineage differentiation capabilities based on the exploration of B cell subpopulations in DLBCL and normal lymph tissues at the single-cell level. Notably, a high infiltration of cancer stem cell-like B cells correlated with a poor prognosis, potentially due to immune evasion mediated by low expression of major histocompatibility complex molecules. Furthermore, we identified key transcription factor regulatory networks regulated by Conclusions: Our research provides a systematic description of a specific cancer stem cell-like B cell subpopulation associated with a poor prognosis in DLBCL. This study enhances our understanding of CSCs and identifies potential therapeutic targets for refractory or recurrent DLBCL patients.

Indexed as

Lymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinB-LymphocytesDNA Copy Number VariationsHumansNeoplasm Recurrence, LocalTumor Microenvironmentbulk RNA sequencingcancer stem celldiffuse large B cell lymphomaimmune escapesingle-cell RNA sequencingtranscription factor

Identifiers

PMID38149239
PMCPMC10750418
OpenAlexW4389569561

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.